Share Twitter LinkedIn Facebook Email Pascal Besman Chief Operating Officer at PharmaMar discusses Emerging New Agents In SCLC. At ESMO Oncology Conference – Munich, Germany On October 19, 2018. Advertisement
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read
